Piper Sandler Maintains Overweight on Pulmonx, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jason Bednar maintains an Overweight rating on Pulmonx (NASDAQ:LUNG) but lowers the price target from $14 to $12.
August 01, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler analyst Jason Bednar maintains an Overweight rating on Pulmonx but lowers the price target from $14 to $12.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100